Tech transfer offices are under increasing pressure to generate revenue, but an innovative tech transfer strategy can help them deliver.

Tech transfer offices are still defined by major licensing blockbusters – for example Northwestern’s royalties from epilepsy drug Lyrica or Columbia’s Axel patents, which cover a method of introducing foreign proteins into nucleated cells – but the field is taking on new dimensions as universities increasingly see those offices as critical revenue drivers. As a result, the future looks more dynamic, sustainable and exciting for all involved.

While the traditional focus of tech transfer offices has been to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?